Followers | 437 |
Posts | 42954 |
Boards Moderated | 2 |
Alias Born | 05/08/2006 |
![](https://investorshub.advfn.com/uicon/72042.png?cb=1480458323)
Wednesday, December 09, 2009 11:30:09 AM
Every day, more than 20,000 people die from some form of cancer worldwide. In the U.S., it’s approximately 1,500 deaths from cancer every day (more than 10 times the number of people that die in automobile accidents). Cancer is the second leading cause of death in the U.S., next to heart disease, accounting for nearly a quarter of all recorded deaths. There are many types of cancer, with each kind being more or less deadly than others. But, overall, if you do get cancer, there’s nearly a 50% chance that it will eventually take your life. The unique nature of the disease calls for what has been termed a magic bullet, something that can detect and hit only cells that are cancerous.
Although it is estimated that nearly a quarter of all cancers could be prevented by basic lifestyle changes, such as not smoking, eating a healthier diet (more fruits and vegetables), exercising, and generally maintaining a suitable weight, that still leaves over 400,000 cancer deaths in America alone believed unrelated to lifestyle.
Nevertheless, in spite of these grim statistics, there is more reason for optimism now than ever. That’s because scientists are learning how to work at the cellular and even molecular level in ways that were impossible before. This is critical, because cancer involves events at the micro sub-cellular level, making it difficult to attack with macro techniques.
The sub-cellular nature of cancer is emphasized by recent discoveries highlighting the role that genetics can play. For example, scientists have found that the absence of a single gene, called the GSTP gene, can increase the number of bowel tumors by a factor of 50. Other scientists have determined that certain naturally produced enzymes can have a dramatic effect on cancerous growths. Understanding the work of genes in cancer development can allow scientists to anticipate and treat various cancers before they become deadly, and such discoveries are now being made on a regular basis.
With heart disease, doctors can perform bypass surgery or provide other effective treatments that do not require manipulation of the inner workings of cells. With cancer, however, such approaches are a little like using an elephant gun to rid your house of ants. The real target is so small and elusive that good cells tend to get damaged or destroyed along with the bad. Although significant strides have been made to improve chemotherapy, radiation, and other macro treatments, progress against cancer has been frustratingly slow. Death rates are finally starting to decline, but scientists know now that the real achievements will be in the future, and probably the near future, as new technologies make it possible to deal with cancer on its own level. Rather than a single magic bullet, there will be many, operating in a carefully choreographed and highly focused attack on a particular cancer, including guiding assaults by the body’s own immune system.
TapImmune, Inc. (OTCBB: TPIV) is a good example of the new companies developing smart drugs to help the body identify and destroy cancerous cells. TapImmune’s vaccine technology is based upon helping individual cells better send up red flags whenever they become cancerous or infected with pathogens. This improved signaling allows the body’s immune system to destroy the cells before they become dangerous.
In addition to TapImmune, and giants like Pfizer (NYSE: PFE), there are a number of publicly traded companies focused on cancer research, drugs, and treatment, including:
• Abraxis Bio Science, Inc. (NASDAQ: ABII)
• Antigenics, Inc. (NASDAQ: AGEN)
• Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA)
• Infinity Pharmaceuticals, Inc. (NASDAZ: INFI)
• Northwest Biotherapeutics, Inc. (OTCBB: NWBO)
• Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)
• Lixte Biotechnology Holdings, Inc. (OTCBB: LIXT)
• Access Pharmaceuticals, Inc. (OTCBB: ACCP)
• Burzynski Research Institute (OTCBB: BZYR)
• Cel-Sci Corp. (NYSE Amex: CVM)
Recent MRKR News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:47:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:39:13 PM
- Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/14/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:12:59 AM
- Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma • GlobeNewswire Inc. • 08/12/2024 11:00:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM